Aβ25-35 injection into the temporal cortex induces chronic inflammation that contributes to neurodegeneration and spatial memory impairment in rats

Journal of Alzheimer's Disease

Volumn 30, Issue 3, 2012, Pages 505-522

  Diaz, Alfonso ^a,b,c   Limon, Daniel ^a   Chávez, Raúl ^b   Zenteno, Edgar ^b   Guevara, Jorge ^b  

^a BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Alzheimer's disease; astrocytes; cytokines; iNOS; memory; microglia; neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEARNING; MALE; MAZE TEST; MEMORY DISORDER; MICROGLIA; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TASK PERFORMANCE; TEMPORAL CORTEX;

EID: 84862880408     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111979     Document Type: Article

References (63)

1. Joshi S, Morley JE (2006) Cognitive impairment. Med Clin North Am 90, 769-787.
2. WalshDM,Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193.
3. Maccioni RB, Mũnoz JP, Barbeito L (2001) The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 32, 367-381.
4. McGeer PL, McGeer EG (2006) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28, 639-647.
5. Heneka MT, Rodŕ?guez JJ, Verkhratsky A (2010) Neuroglia in neurodegeneration. Brain Res Rev 63, 189-211.
6. Meda L, Baron P, Scarlato G (2001) Glial activation in Alzheimer's disease: The role of Abeta and its associated proteins. Neurobiol Aging 22, 885-893.
7. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C (2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 202, 13-23.
8. Drouet B, Pinçon-Raymond M, Chambaz J, Pillot T (2000) Molecular basis of Alzheimer's disease. Cell Mol Life Sci 57, 705-715.
9. Turner PR, O'Connor K, TateWP, AbrahamWC(2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32.
10. Duyckaerts C (2004) Looking for the link between plaques and tangles. Neurobiol Aging 25, 735-739.
11. Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706, 181-193.
12. Andersen JM, Myhre O, Aarnes H, Vestad TA, Fonnum F (2003) Identification of the hydroxyl radical and other reactive oxygen species in human neutrophil granulocytes exposed to a fragment of the amyloid beta peptide. Free Radic Res 37, 269-279.
13. Stepanichev M, Zdobnova I, Zarubenko I, Lazareva N, Gulyaeva NV (2006) Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat. Behav Brain Res 175, 352-361.
14. Chen P, Shen A, ZhaoW, Baek SJ,Yuan H,HuJ (2009) Raman signature from brain hippocampus could aid Alzheimer's disease diagnosis. Appl Opt 48, 4743-4748.
15. Kubo T, Nishimura S, Kumagae Y, Kaneko I (2002) In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70, 474-483.
16. Liḿon ID, D́?az A, Mendieta L, Chamorro G, Espinosa B, Zenteno E, Guevara J (2009) Amyloid-beta (25-35) impairs memory and increases NO in the temporal cortex of rats. Neurosci Res 63, 129-137.
17. Diaz A, De Jeśus L, Mendieta L, Calvillo M, Espinosa B, Zenteno E, Guevara J, Liḿon ID (2010) The amyloid-beta25-35 injection into the CA1 region of the neonatal rat hippocampus impairs the long-term memory because of an increase of nitric oxide. Neurosci Lett 468, 151-155.
18. Diaz A, Mendieta L, Zenteno E, Guevara J, Limon ID (2011) The role of NOS in the impairment of spatial memory and damaged neurons in rats injected with amyloid beta 25-35 into the temporal cortex. Pharmacol Biochem Behav 98, 67-75.
19. Bandyopadhyay S, Hartley DM, Cahill CM, Lahiri DK, Chattopadhyay N, Rogers JT (2006) Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. J Neurosci Res 84, 106-118.
20. Rosales-Corral S, Tan DX, Reiter RJ, Valdivia-Veĺazquez M, Acosta-Mart́?nez JP, Ortiz GG (2004) Kinetics of the neuroinflammation- oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta onto the hippocampus in vivo. J Neuroimmunol 150, 20-28.
21. Yin Y,Wen S, Li G,Wang D (2009) Hypoxia enhances stimulating effect of amyloid beta peptide (25-35) for interleukin 17 and T helper lymphocyte subtype 17 upregulation in cultured peripheral blood mononuclear cells. Microbiol Immunol 53, 281-286.
22. Chiarini A, Whitfield J, Bonafini C, Chakravarthy B, Armato U, Dal Pr̀a I (2010) Amyloid-(25-35), an amyloid-(1-42) surrogate, and proinflammatory cytokines stimulate VEGF-A secretion by cultured, early passage, normoxic adult human cerebral astrocytes. J Alzheimers Dis 21, 915-926.
23. Cuevas E, Liḿon D, Ṕerez-Severiano F, D́?az A, Ortega L, Zenteno E, Guevara J (2009) Antioxidant effects of epicatechin on the hippocampal toxicity caused by amyloid-beta 25-35 in rats. Eur J Pharmacol 616, 122-127.
24. Cuevas E, Lantz SM, Tob́on-Velasco JC, Newport GD, Wu Q, Virmani A, Ali SF, Santamaŕ?a A (2011) On the in vivo early toxic properties of A-beta 25-35 peptide in the rat hippocampus: Involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression. Neurotoxicol Teratol 33, 288-296.
25. Paxino G,Watson C (1998) The rat brain in stereotaxic coordinates. Elsevier Academic Press, Amsterdam.
26. Olton DS, Samuelson RJ (1976) Remembrance of places passed: Spatial memory in rats. J Exp Psychol Animal Behav Process 2, 97-116.
27. Liḿon ID, Mendieta L, D́?az A, Chamorro G, Espinosa B, Zenteno E, Guevara J (2009) Neuroprotective effect of alphaasarone on spatial memory and nitric oxide levels in rats injected with amyloid-beta(25-35). Neurosci Lett 453, 98-103.
28. Stepanichev MI, Zdobnova IM, Zarubenko II, Lazareva NA, Guliaeva NV (2004) Effects of central administration of beta-amyloid peptide (25-35): Pathomorphological changes in the hippocampus and impairments of spatial memory. Zh Vyssh Nerv Deiat Im I P Pavlova 54, 705-711.
29. Kiyota Y, Miyamoto M, Nagaoka A (1991) Relationship between brain damage and memory impairment in rats exposed to transient forebrain ischemia. Brain Res 538, 295-302.
30. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS (1982) Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem 126, 131-138.
31. Dinarello CA, Thompson RC (1991) Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12, 404-410.
32. Young EE, Baumbauer KM, Elliot A, Joynes RL (2007) Lipopolysaccharide induces a spinal learning deficit that is blocked by IL-1 receptor antagonism. Brain Behav Immun 21, 748-757.
33. Qureshi AA, Tan X, Reis JC, Badr MZ, Papasian CJ, Morrison DC, Qureshi N (2011) Inhibition of nitric oxide in LPS-stimulated macrophages of young and senescent mice by delta-tocotrienol and quercetin. Lipids Health Dis 10, 239-346.
34. Selkoe DJ (2002) Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110, 1375-1381.
35. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
36. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F (2004) Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid (25-35). J Neuroimmunol 93, 45-52.
37. Walsh DM, Selkoe DJ (2007) A beta oligomers a decade of discovery. J Neurochem 101, 1172-1184.
38. Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition-The case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50, 2041-2056.
39. Eikelenboom P, van GoolWA(2004) Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 111, 281-294.
40. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M (2005) Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 9, 381-393.
41. Veerhuis R, Boshuizen RS, Familian A (2005) Amyloid associated proteins in Alzheimer's and prion disease. Curr Drug Targets CNS Neurol Disord 4, 235-248.
42. Tuppo EE, Arias HR (2005) The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37, 289-305.
43. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
44. BenvenisteEN(1992) Inflammatory cytokines within the central nervous system: Sources, function, and mechanism of action. Am J Physiol 263, 1-16.
45. Jin W, Wang H, Yan W, Xu L, Wang X, Zhao X, Yang X, Chen G, Ji Y (2008) Disruption of Nrf2 enhances upregulation of nuclear factor-kappa B activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediators Inflamm 2008, 1-7.
46. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361, 888-898.
47. Giulian D (1998) A strategy for identifying immunosuppressive therapies for Alzheimer disease. Alzheimer Dis Assoc Disord 12, S7-14.
48. Mc Geer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 47, 425-432.
49. Heneka MT, O'Banion MK (2007) Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184, 69-91.
50. Rossi F, Bianchini E (1996) Synergistic induction of nitric oxide by beta-amyloid and cytokines in astrocytes. Biochem Biophys Res Commun 225, 474-478.
51. Heneka MT, O'Banion MK (2007) Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184, 69-91.
52. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R (2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237, 123-130.
53. Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128, 988-1002.
54. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT (2008) Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 29, 5-37.
55. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, Suzumura A (2008) Production and functions of IL-17 in microglia. J Neuroimmunol 194, 54-61.
56. Heneka MT, Galea E, Gavriluyk V, Dumitrescu-Ozimek L, Daeschner J, O'Banion MK, Weinberg G, Klockgether T, Feinstein DL (2002) Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation implications for Alzheimer's disease. J Neurosci 22, 2434-2442.
57. Hass S, Weidemann A, Utermann G, Baier G (2002) Intracellular apolipoprotein E affects Amyloid Precursor Protein processing and amyloid Abeta production in COS-1 cells. Mol Genet Genomics 265, 791-800.
58. Ferńandez-Vizarra P, Ferńandez AP, Castro-Blanco S, Encinas JM, Serrano J, Bentura ML, Mũnoz P, Mart́?nez-Murillo R, Rodrigo J (2004) Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiol Dis 15, 287-305.
59. Malinski T (2007) Nitric oxide and nitroxidative stress in Alzheimer's disease. J Alzheimers Dis 11, 207-218.
60. Stepanichev MY, Onufriev MV, Yakovlev AA, Khrenov AI, Peregud DI, Vorontsova ON, Lazareva NA, Gulyaeva NV (2008) Amyloid-beta (25-35) increases activity of neuronal NO-synthase in rat brain. Neurochem Int 52, 1114-1124.
61. Rodrigo J, Ferńandez-Vizarra P, Castro-Blanco S, Bentura ML, Nieto M, Ǵomez-Isla T, Mart́?nez-Murillo R, MartInez A, Serrano J, Ferńandez AP (2004) Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice. Neuroscience 128, 73-89.
62. Moncada S, Bolãnos JP (2006) Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 97, 1676-1689.
63. Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, Ṕerault-Pochat MC, Lafay-Chebassier C (2010) Imipramine, In part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 332, 505-514.